A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles

Autores
Moreno Torrejon, Laura; Lopez Urbina, L.; Farias, Cristina Elena; Domingue, G.; Donadeu, M.; Dungu, B.; García, H. H.; Gomez Puerta, L. A.; Lanusse, Carlos Edmundo; González, A. E.
Año de publicación
2012
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Oxfendazole (OFZ) is efficacious for porcine cysticercosis at 30mg/kg. OFZ is not registered to be used at this dose. The assessment of the OFZ and metabolites [(fenbendazole sulphone (FBZSO2), fenbendazole (FBZ)] plasma pharmacokinetic and tissue residue profiles after its oral administration to pigs and the withdrawal period for human consumption were reported. Forty-eight pigs allocated into two groups received OFZ (30mg/kg) orally as a commercial (CF) or as experimental formulation (SMF). Samples (blood, muscle, liver, kidney and fat) were collected over 30days post-treatment and analyzed by HPLC. OFZ was the main compound recovered in plasma, followed by FBZSO2 and low FBZ concentrations. OFZ AUC0-LOQ (209.9±33.9μg·h/ml) and Cmax (5.40±0.65μg/ml) parameters for the CF tended to be higher than those for the SMF (AUC0-LOQ: 159.4±18.3μgh/ml, Cmax: 3.80±0.35μg/ml). The highest total residue (OFZ+FBZSO2+FBZ) concentrations were quantified in liver, followed by kidney, muscle and fat tissue. FBZSO2 residue levels were the highest found in muscle (0.68±0.39μg/g) and fat (0.69±0.39μg/g). In liver and kidney the highest residues corresponded to FBZ (5.29±4.36μg/g) and OFZ (2.86±0.75μg/g), respectively. A withdrawal time of 17days post-treatment was established before tissues are delivered for human consumption.
Fil: Moreno Torrejon, Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina
Fil: Lopez Urbina, L.. Universidad Nacional Mayor de San Marcos; Perú
Fil: Farias, Cristina Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina
Fil: Domingue, G.. Express Microbiology Ltd.; Reino Unido
Fil: Donadeu, M.. Global Alliance for Livestock Veterinary Medicines; Reino Unido
Fil: Dungu, B.. Global Alliance for Livestock Veterinary Medicines; Reino Unido
Fil: García, H. H.. Universidad Peruana Cayetano Heredia; Perú. Instituto Nacional de Ciencias Neurológicas; Perú. Cysticercosis Working Group; Perú
Fil: Gomez Puerta, L. A.. Universidad Nacional Mayor de San Marcos; Perú. Cysticercosis Working Group; Perú
Fil: Lanusse, Carlos Edmundo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina
Fil: González, A. E.. Universidad Nacional Mayor de San Marcos; Perú. Cysticercosis Working Group; Perú
Materia
Cysticercosis
Oxfendazole
Pharmacokinetics
Tissue Residues
Withdrawal Time
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/69618
Acceder
id CONICETDig_abc9ab482f1cdd6170c2021a8b44ba23
oai_identifier_str oai:ri.conicet.gov.ar:11336/69618
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profilesMoreno Torrejon, LauraLopez Urbina, L.Farias, Cristina ElenaDomingue, G.Donadeu, M.Dungu, B.García, H. H.Gomez Puerta, L. A.Lanusse, Carlos EdmundoGonzález, A. E.CysticercosisOxfendazolePharmacokineticsTissue ResiduesWithdrawal Timehttps://purl.org/becyt/ford/2.11https://purl.org/becyt/ford/2Oxfendazole (OFZ) is efficacious for porcine cysticercosis at 30mg/kg. OFZ is not registered to be used at this dose. The assessment of the OFZ and metabolites [(fenbendazole sulphone (FBZSO2), fenbendazole (FBZ)] plasma pharmacokinetic and tissue residue profiles after its oral administration to pigs and the withdrawal period for human consumption were reported. Forty-eight pigs allocated into two groups received OFZ (30mg/kg) orally as a commercial (CF) or as experimental formulation (SMF). Samples (blood, muscle, liver, kidney and fat) were collected over 30days post-treatment and analyzed by HPLC. OFZ was the main compound recovered in plasma, followed by FBZSO2 and low FBZ concentrations. OFZ AUC0-LOQ (209.9±33.9μg·h/ml) and Cmax (5.40±0.65μg/ml) parameters for the CF tended to be higher than those for the SMF (AUC0-LOQ: 159.4±18.3μgh/ml, Cmax: 3.80±0.35μg/ml). The highest total residue (OFZ+FBZSO2+FBZ) concentrations were quantified in liver, followed by kidney, muscle and fat tissue. FBZSO2 residue levels were the highest found in muscle (0.68±0.39μg/g) and fat (0.69±0.39μg/g). In liver and kidney the highest residues corresponded to FBZ (5.29±4.36μg/g) and OFZ (2.86±0.75μg/g), respectively. A withdrawal time of 17days post-treatment was established before tissues are delivered for human consumption.Fil: Moreno Torrejon, Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Lopez Urbina, L.. Universidad Nacional Mayor de San Marcos; PerúFil: Farias, Cristina Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Domingue, G.. Express Microbiology Ltd.; Reino UnidoFil: Donadeu, M.. Global Alliance for Livestock Veterinary Medicines; Reino UnidoFil: Dungu, B.. Global Alliance for Livestock Veterinary Medicines; Reino UnidoFil: García, H. H.. Universidad Peruana Cayetano Heredia; Perú. Instituto Nacional de Ciencias Neurológicas; Perú. Cysticercosis Working Group; PerúFil: Gomez Puerta, L. A.. Universidad Nacional Mayor de San Marcos; Perú. Cysticercosis Working Group; PerúFil: Lanusse, Carlos Edmundo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: González, A. E.. Universidad Nacional Mayor de San Marcos; Perú. Cysticercosis Working Group; PerúPergamon-Elsevier Science Ltd2012-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/69618Moreno Torrejon, Laura; Lopez Urbina, L.; Farias, Cristina Elena; Domingue, G.; Donadeu, M.; et al.; A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles; Pergamon-Elsevier Science Ltd; Food And Chemical Toxicology; 50; 10; 10-2012; 3819-38250278-6915CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.fct.2012.07.023info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0278691512005017info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:04:04Zoai:ri.conicet.gov.ar:11336/69618instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:04:04.493CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles
title A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles
spellingShingle A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles
Moreno Torrejon, Laura
Cysticercosis
Oxfendazole
Pharmacokinetics
Tissue Residues
Withdrawal Time
title_short A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles
title_full A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles
title_fullStr A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles
title_full_unstemmed A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles
title_sort A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles
dc.creator.none.fl_str_mv Moreno Torrejon, Laura
Lopez Urbina, L.
Farias, Cristina Elena
Domingue, G.
Donadeu, M.
Dungu, B.
García, H. H.
Gomez Puerta, L. A.
Lanusse, Carlos Edmundo
González, A. E.
author Moreno Torrejon, Laura
author_facet Moreno Torrejon, Laura
Lopez Urbina, L.
Farias, Cristina Elena
Domingue, G.
Donadeu, M.
Dungu, B.
García, H. H.
Gomez Puerta, L. A.
Lanusse, Carlos Edmundo
González, A. E.
author_role author
author2 Lopez Urbina, L.
Farias, Cristina Elena
Domingue, G.
Donadeu, M.
Dungu, B.
García, H. H.
Gomez Puerta, L. A.
Lanusse, Carlos Edmundo
González, A. E.
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Cysticercosis
Oxfendazole
Pharmacokinetics
Tissue Residues
Withdrawal Time
topic Cysticercosis
Oxfendazole
Pharmacokinetics
Tissue Residues
Withdrawal Time
purl_subject.fl_str_mv https://purl.org/becyt/ford/2.11
https://purl.org/becyt/ford/2
dc.description.none.fl_txt_mv Oxfendazole (OFZ) is efficacious for porcine cysticercosis at 30mg/kg. OFZ is not registered to be used at this dose. The assessment of the OFZ and metabolites [(fenbendazole sulphone (FBZSO2), fenbendazole (FBZ)] plasma pharmacokinetic and tissue residue profiles after its oral administration to pigs and the withdrawal period for human consumption were reported. Forty-eight pigs allocated into two groups received OFZ (30mg/kg) orally as a commercial (CF) or as experimental formulation (SMF). Samples (blood, muscle, liver, kidney and fat) were collected over 30days post-treatment and analyzed by HPLC. OFZ was the main compound recovered in plasma, followed by FBZSO2 and low FBZ concentrations. OFZ AUC0-LOQ (209.9±33.9μg·h/ml) and Cmax (5.40±0.65μg/ml) parameters for the CF tended to be higher than those for the SMF (AUC0-LOQ: 159.4±18.3μgh/ml, Cmax: 3.80±0.35μg/ml). The highest total residue (OFZ+FBZSO2+FBZ) concentrations were quantified in liver, followed by kidney, muscle and fat tissue. FBZSO2 residue levels were the highest found in muscle (0.68±0.39μg/g) and fat (0.69±0.39μg/g). In liver and kidney the highest residues corresponded to FBZ (5.29±4.36μg/g) and OFZ (2.86±0.75μg/g), respectively. A withdrawal time of 17days post-treatment was established before tissues are delivered for human consumption.
Fil: Moreno Torrejon, Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina
Fil: Lopez Urbina, L.. Universidad Nacional Mayor de San Marcos; Perú
Fil: Farias, Cristina Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina
Fil: Domingue, G.. Express Microbiology Ltd.; Reino Unido
Fil: Donadeu, M.. Global Alliance for Livestock Veterinary Medicines; Reino Unido
Fil: Dungu, B.. Global Alliance for Livestock Veterinary Medicines; Reino Unido
Fil: García, H. H.. Universidad Peruana Cayetano Heredia; Perú. Instituto Nacional de Ciencias Neurológicas; Perú. Cysticercosis Working Group; Perú
Fil: Gomez Puerta, L. A.. Universidad Nacional Mayor de San Marcos; Perú. Cysticercosis Working Group; Perú
Fil: Lanusse, Carlos Edmundo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina
Fil: González, A. E.. Universidad Nacional Mayor de San Marcos; Perú. Cysticercosis Working Group; Perú
description Oxfendazole (OFZ) is efficacious for porcine cysticercosis at 30mg/kg. OFZ is not registered to be used at this dose. The assessment of the OFZ and metabolites [(fenbendazole sulphone (FBZSO2), fenbendazole (FBZ)] plasma pharmacokinetic and tissue residue profiles after its oral administration to pigs and the withdrawal period for human consumption were reported. Forty-eight pigs allocated into two groups received OFZ (30mg/kg) orally as a commercial (CF) or as experimental formulation (SMF). Samples (blood, muscle, liver, kidney and fat) were collected over 30days post-treatment and analyzed by HPLC. OFZ was the main compound recovered in plasma, followed by FBZSO2 and low FBZ concentrations. OFZ AUC0-LOQ (209.9±33.9μg·h/ml) and Cmax (5.40±0.65μg/ml) parameters for the CF tended to be higher than those for the SMF (AUC0-LOQ: 159.4±18.3μgh/ml, Cmax: 3.80±0.35μg/ml). The highest total residue (OFZ+FBZSO2+FBZ) concentrations were quantified in liver, followed by kidney, muscle and fat tissue. FBZSO2 residue levels were the highest found in muscle (0.68±0.39μg/g) and fat (0.69±0.39μg/g). In liver and kidney the highest residues corresponded to FBZ (5.29±4.36μg/g) and OFZ (2.86±0.75μg/g), respectively. A withdrawal time of 17days post-treatment was established before tissues are delivered for human consumption.
publishDate 2012
dc.date.none.fl_str_mv 2012-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/69618
Moreno Torrejon, Laura; Lopez Urbina, L.; Farias, Cristina Elena; Domingue, G.; Donadeu, M.; et al.; A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles; Pergamon-Elsevier Science Ltd; Food And Chemical Toxicology; 50; 10; 10-2012; 3819-3825
0278-6915
CONICET Digital
CONICET
url http://hdl.handle.net/11336/69618
identifier_str_mv Moreno Torrejon, Laura; Lopez Urbina, L.; Farias, Cristina Elena; Domingue, G.; Donadeu, M.; et al.; A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles; Pergamon-Elsevier Science Ltd; Food And Chemical Toxicology; 50; 10; 10-2012; 3819-3825
0278-6915
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1016/j.fct.2012.07.023
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0278691512005017
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Pergamon-Elsevier Science Ltd
publisher.none.fl_str_mv Pergamon-Elsevier Science Ltd
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269835434655744
score 13.13397

Publicaciones similares